Dr Miroslav Ravic MD, PhD
Chief Executive Officer, Chief Science Officer & Chief Medical Officer
Dr Ravic has 30 years of experience covering clinical practice, medical science and drug development of biologics and small molecules. He has a PhD in Clinical Pharmacology from London University, an MD, and an MSc in Experimental Pharmacology with specialisation in Clinical Pharmacology from the University of Belgrade.
He has authored and presented numerous scientific papers. His previous posts include senior development positions at Boehringer Ingelheim, Eisai Europe and Antisoma in London. Dr Ravic has completed around 100 clinical trials and specialises in bridging the transition from preclinical to clinical development, having created a proven methodology for increasing speed and reducing costs to achieve proof of concept.
Dr Steve Felstead
Dr Felstead retired from the position of Vice President, Head of Clinical Research, Pharmatherapeutics Division, Pfizer Inc in April 2014. He joined Pfizer in 1989, having qualified in Medicine at Leeds University UK in 1982. Dr Felstead was appointed Head of Clinical Research in January 2009 with responsibility for research projects up to Proof of Concept (Phase IIa) in the following Therapeutic Areas: Neuroscience, Cardiovascular and Metabolic Disease, Anti-Infectives, Pain and Regenerative Medicine. Dr Felstead previously served as Development Therapeutic Area Head for Allergy and Respiratory medicines through to Phase IIIb. As well as line management roles, Dr Felstead also led multiple development project teams including the Viagra (sildenafil) team when the first pulmonary hypertension study was being designed, which led to the successful Revatio development program. From 2003-2007 he led the Celsentri/Selzentry (maraviroc) team through to successful transatlantic registration of this novel anti-retroviral medicine.
Since retirement Dr Felstead consults widely on various programmes for VC, Biotech, and Pharma. Dr Felstead is a member of Innovate UK, Biomedical Catalyst Late Stage Award committee, a member of AdALta Limited’s Scientific Advisory Board, acting CMO for Mironid, a non-executive director with MGB Biopharma and a member of Tricapital Group, which invests in emerging businesses in the Scottish Borders and neighbouring counties.
Mr Adam Christie
Adam has a broad background in the pharmaceutical and biotechnology industry. He is a business developer and marketer with direct experience of drug and device development and the capital markets. Adam is CEO of Calcivis, a dental imaging business he started in 2011. Previously, as Chief Business Officer at PowderMed, he led business development and commercial strategy which culminated in the successful sale of the company to Pfizer in late 2006, two and a half years after a series ‘A’ venture funding round.
His earlier career included roles in business development, marketing and R&D at PPL Therapeutics, GlaxoSmithKline, Abbott Laboratories and Schering AG, and as a City analyst at ABN Amro Hoare Govett. His educational background includes a BSc in Pharmacology from Southampton University and an MBA from Warwick Business School.
Mr John Waddell
John Waddell stepped down as CEO of Archangel Investors Ltd, who have led each funding round in MGB Biopharma to date, in September 2015 after 10 years at the helm. John is a lawyer with wide experience in industry and corporate finance in the UK and overseas. He continues to advise Archangels and is on the boards of IndigoLighthouse Group Limited, NCTech Limited and Northern 3 VCT PLC. He is also on the advisory boards of Amadeus & Angels Seed Fund and Seraphim Capital.
Mr Ken Fyvie
Ken has 40 years’ experience of the life sciences sector accumulated through working in the pharmaceutical industry in sales and marketing roles, in investment research of the sector and related corporate finance, and as a member of the management group at PA Consulting Group. At PA his activities emphasised business strategy, new product development and commercialisation, business performance improvement and organisational development. During his time at PA, Ken worked with many of the companies in the sector, including Big Pharma, SMEs / Specialists and start-ups.
Since retiring from PA in late 2013, Ken has worked independently as a consultant, and collaborated with several providers of specialist services to the life sciences sector.
In early 2015 Ken joined the board of Cytomos Ltd., a young company developing a novel approach to biological cell analysis, where his understanding of the market, product development experience and management insights have contributed to Cytomos’ progress. Ken joined the board of MGB Biopharma as Chairman in July 2016 where his experience in drug development, of ant-infectives in particular, and of business management, will provide an assist to the executive team and board.
Mr Raymond Spencer ACA
Chief Financial Officer
Raymond Spencer has over 25 years experience as a senior financial officer in biotech. For 12 years he was the CFO of LSE listed Antisoma plc. Whilst at Antisoma he was instrumental in completing the IPO in 1998, and in several fund-raising rounds, totalling over £100 million, as well as the acquisition of two private biotech companies. He was also instrumental in the closing of three licensing deals with big pharma.